Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Moon, Jung Yeon; Lee, Kyung Eun; Chang, Byung Chul; Jeong, Eurim; Jeong, Hotcherl; Gwak, Hye Sun
• Is Part Of: Pharmaocogenetics and genomics. Volume 25:Issue 1(2015:Jan.)
• Publication Date: 2015-01
• Subjects: Pharmacogenetics -- Periodicals; Pharmacogenomics -- Periodicals; Genetic toxicology -- Periodicals; Biomedical genetics -- Periodicals; 615.7
• DOI: 10.1097/FPC.0000000000000103
• Languages: English
• ISSNs: 1744-6872

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>A possible association between the combination of genetic variations in hepatocyte nuclear factor 4α (HNF4α) and constitutive androstane receptor (CAR) and the stable doses of warfarin was examined in patients from the Ewha–Severance Treatment (EAST) Group of Warfarin. Around 42.5% of the overall interindividual variability in warfarin dose requirements was explained by the multivariate regression model; the <italic>vitamin K epoxide reductase complex 1</italic> (<italic>VKORC1</italic>) genotype accounted for 29.6%, the <italic>cytochrome P450</italic> (<italic>CYP</italic>) <italic>2C9</italic> genotype for 4.3%, age for 3.6%, the <italic>CYP4F2</italic> genotype for 3.3%, and <italic>CAR/HNF4α</italic> (rs2501873/rs3212198) for 1.7%. Our results showed that the combination of <italic>CAR</italic> and <italic>HNF4α</italic> genotypes could be determinants of stable warfarin doses.</p> </sec> </abstract>